Navigation Links
CPC Launches New Web Site Highlighting Medical, Research and Technical Panel, MedClose(TM) VCS Animated Video
Date:11/11/2008

http://www.CPCMedDevices.com provides latest information to medical and investment

communities

SARASOTA, Fla., Nov. 11 /PRNewswire-FirstCall/ -- CPC of America, Inc. (CPC) (OTC Bulletin Board: CPCF), today launched its new Web site, http://www.CPCMedDevices.com, to provide the medical and investment communities with a wealth of information on the company and its investigational product, MedClose(TM). CPC is a company focused on innovating medical devices that deliver improved safety and effectiveness and enhance the quality of patient care in endovascular procedures. It is pursuing worldwide commercial applications for MedClose(TM), an extravascular closure system (VCS) intended for use with a biological sealant to seal the femoral arterial puncture site following diagnostic or interventional catheterization procedures.

The Web site features CPC's panel of medical, research and technical advisors, which includes:

-- James R. Margolis, M.D., F.A.C.C., the pioneer of angioplasty in the Southeastern United States and the sixth person in the World to perform coronary angioplasty. He is American Board certified in Internal Medicine, Interventional Cardiology and Cardiovascular Disease.

-- Fred L. Ma, M.D., Ph. D., a board-certified neurosurgeon with more than 25 years of clinical experience and experience in the development and commercialization of more than 20 new drugs and medical devices.

-- Grace T. Bartoo, Ph. D., RAC, CBA, co-founder of Decus Biomedical with more than 25 years of seeing medical devices through clinical trials and regulatory approval.

-- Marc L. Bartoo, Ph. D., RAC, co-founder and technical services manager of Decus Biomedical, with expertise in regulatory affairs, design control, verification and validation.

-- Steve Jwanouskos, a regulatory and clinical consultant with more than 20 years of experience in the development of innovative medical technologies, including extensive expertise in the development of novel medical devices.

-- Gerhard Fromel, DIPL. Ing, the authorized European representative for CPC with more than 25 years of experience in medical research, development and regulatory affairs in the European Union.

Further, the Web site displays an animated demonstration of the MedClose(TM) VCS in action. The animation highlights the unique design features of the MedClose(TM) VCS, which are intended to allow for significant reduction in time to hemostasis and need for manual compression. The MedClose(TM) device is intended for use with any approved natural fibrin sealant, leaving no permanent implant behind.

CPC Chairman President and CEO Rod Shipman said, "As we move closer to commercialization, we have upgraded our Web site to ensure that the medical and investment communities understand both our company and our products. We

will continue to populate the site with additional content and our latest news to keep our important constituents well informed."

About CPC

CPC of America, Inc. (CPC) is focused on designing, developing and commercializing innovative medical devices that deliver improved safety and effectiveness and enhance the quality of patient care in endovascular procedures. CPC's is currently developing MedClose(TM), an investigational*- stage vascular closure system (VCS) that is intended to seal the femoral arterial puncture site following diagnostic or interventional catheterization procedures.

Forward Looking Statements

The statements contained in this press release that are not historical are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements, without limitation, regarding the Company's expectations, beliefs, intentions or strategies regarding the future. Such forward-looking statements relate to, among other things: (1) the Company's continuing development of its MedClose(TM) vascular closure system, (2) the Company's expectations concerning regulatory approvals of the MedClose system and the commencement of revenue producing operations based on the sale or licensing of the MedClose, (3) the business relationship between the Company and its panel of advisors and the expected benefits to the Company from such relationship, and (4) the commencement of manufacturing of the MedClose system. These statements are qualified by important factors that could cause the Company's actual results to differ materially from those reflected by the forward-looking statements. Such factors include but are not limited to: (1) the Company's ability to finance the continued development and commencement of manufacturing of the MedClose system, (2) Regulatory approvals of the MedClose system, (3) the general risks and uncertainties inherent in any business relationship such as the those entered into between the Company and its medical, research and technical advisors, and (4) those other risks and factors described from time to time in the Company's reports filed with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and subsequently filed Forms 10-Q and Forms 8-K. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.


'/>"/>
SOURCE CPC of America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. United Spinal Association Launches VetsFirst.org Help Center: The Next Generation Veterans Service Organization
2. Ground-breaking New Reality Show Hair Loss Confidential Launches First Webisode
3. NaturalNews Launches Print-On-Demand, Publishing Services for Book Authors, Self Publishers
4. Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
5. Blue Cross Launches Statewide Healthy Eating Campaign to Double Number of Minnesotans Eating Fruits, Veggies
6. The Leapfrog Group Launches Updated Hospital Rewards Program
7. Unilens Launches New C-VUE(R) Advanced(TM) Custom Toric Lens
8. Masimo Launches First Non-adhesive Pulse Oximetry Sensor Designed For Extremely Low Birth Weight Babies
9. AmeriCares Launches India Operations
10. HealthFitness Launches New Preventive Health Solution for Small Employers
11. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... 22, 2017 , ... Pivot Point Consulting, a ... as the firm’s new Consulting Services Executive. Mr. Tisch will oversee all aspects ... assisting clients with initial vendor selection and pre-implementation planning through go-live support and ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: a ... B17 bomber named Edward Koontz. “To Walk Away” is the creation of published author, ... published over two hundred manuscripts in chemistry and religion, as well as four novels. ...
(Date:8/22/2017)... Raleigh, North Carolina (PRWEB) , ... August 22, ... ... senior strategic advisor. Mr. Stewart is the Founder and Managing Member for t4 ... elements that have become critical to his definition of “success”: physician leadership development, ...
(Date:8/21/2017)... ... 22, 2017 , ... Nanoparticle research provides an exciting path ... learning and implementing best practices for containment using ventilated safety enclosures, many of ... a better understanding of a method for safely testing nanotechnology hoods. They will ...
(Date:8/21/2017)... , ... August 21, 2017 , ... Five chefs from ... awareness for Alzheimer’s Family Center. , Guests will be able to vote for ... Plaza, Braised Lamb Shank with Fennel Dill Salad, Feta Cheese Sauce & Garlic Pita ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... 3, 2017  Opioid addiction and other drugs of ... costs and threatening outcomes, were problems taken on directly ... industry that support them, met this week. This according ... that drugs of abuse, procalcitonin and acute kidney injury ... organization,s 69th meeting in San Diego, CA. ...
(Date:8/2/2017)... WASHINGTON , Aug. 2, 2017 CaryRx, a ... same day delivery service for patients in the ... the traditional retail pharmacy by providing delivery of medications through ... scheduled for future delivery or delivered within one hour to ... "We are excited to bring this invaluable service to ...
(Date:7/31/2017)... 7D Surgical, developer of ground breaking surgical navigation technologies, announced ... to support its strategic sales plan in Maryland ... 7D Surgical has entered into an exclusive sales representative agreement ... within those markets. ... Spartan Medical Purchases 7D Surgical ...
Breaking Medicine Technology: